Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilbert W Gleim

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Hypertension (Greenwich, Conn.)|August 17, 2004
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapyJonathan C Fox, Kellie Leight, Santosh C Sutradhar, et al.
Clinical Therapeutics|December 13, 2006
A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertensionGilbert W Gleim, Joseph Rubino, Hongyan Zhang, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 3, 2011
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trialNicholas J A Webb, Chun Lam, Shahnaz Shahinfar, et al.
Kidney International|June 29, 2012
Losartan and enalapril are comparable in reducing proteinuria in childrenNicholas J A Webb, Shahnaz Shahinfar, Thomas G Wells, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2010
Randomized, double-blind, controlled study of losartan in children with proteinuriaNicholas J A Webb, Chun Lam, Tom Loeys, et al.
Journal of the American Society of Nephrology : JASN|May 6, 2005
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyZhongxin Zhang, Shahnaz Shahinfar, William F Keane, et al.
Journal of the American Society of Nephrology : JASN|April 6, 2007
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp, Zhongxin Zhang, Giuseppe Remuzzi, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Hypertension (Greenwich, Conn.)|August 17, 2004
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapyJonathan C Fox, Kellie Leight, Santosh C Sutradhar, et al.
Clinical Therapeutics|December 13, 2006
A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertensionGilbert W Gleim, Joseph Rubino, Hongyan Zhang, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 3, 2011
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trialNicholas J A Webb, Chun Lam, Shahnaz Shahinfar, et al.
Kidney International|June 29, 2012
Losartan and enalapril are comparable in reducing proteinuria in childrenNicholas J A Webb, Shahnaz Shahinfar, Thomas G Wells, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2010
Randomized, double-blind, controlled study of losartan in children with proteinuriaNicholas J A Webb, Chun Lam, Tom Loeys, et al.
Journal of the American Society of Nephrology : JASN|May 6, 2005
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyZhongxin Zhang, Shahnaz Shahinfar, William F Keane, et al.
Journal of the American Society of Nephrology : JASN|April 6, 2007
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp, Zhongxin Zhang, Giuseppe Remuzzi, et al.
Pageof 2